The Intersection of Immunosenescence, Cellular Senescence, and Type 1 Diabetes: Paving the Way for Future...

Immunosenescence, characterized by functional decline and altered phenotypes of immune cells with age, can disturb immune tolerance and promote autoreactive responses. Type 1 diabetes (T1D) has traditionally been viewed as a disease of immune dysregulation that leads to the autoimmune destruction of pancreatic β-cells. Emerging evidence suggests that senescence contributes to both the onset and progression of T1D. Autoreactive T cells are associated not only with β-cell death but also with the induction of β-cell senescence. In parallel, senescent β-cells acquire a senescence-associated secretory phenotype that amplifies local inflammation and increases β-cell vulnerability. These interlinked processes position senescence as a mechanistic bridge between aging, immune dysfunction, and autoimmunity. Importantly, a bidirectional loop appears to exist, in which T1D accelerates immune aging while immunosenescence further exacerbates autoimmunity. Recognizing this interplay highlights senescence as a promising and underexplored therapeutic target. Here, we synthesize current knowledge on immunosenescence and cellular senescence, examine their convergence in T1D pathogenesis, and outline future directions where interventions against senescent pathways could open new opportunities for treatment and prevention.

The relationship between type 1 diabetes (T1D) and immunosenescence has not been deeply investigated. T1D is characterized by immune activation, metabolic stress, and hyperglycemia, which induce chronic low-grade inflammation. These factors are well-established drivers of immunosenescence. We propose that T1D may induce a state of premature immunosenescence, even in relatively young individuals. Immunosenescence is associated with an impaired immune response, reduced tolerance, and production of proinflammatory mediators. These may further exacerbate autoimmunity, creating a self-reinforcing cycle between autoimmunity and immune aging mechanisms. Integrating these perspectives could expand our understanding of disease mechanisms and lead to novel treatment approaches for T1D.